ZAI LAB LIMITED Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ZAI LAB LIMITED (ZLAB) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $6.05 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-26
- ZAI LAB LIMITED right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $6.05M, a 46.01% decline year-over-year.
- ZAI LAB LIMITED right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ZAI LAB LIMITED right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- ZAI LAB LIMITED right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- ZAI LAB LIMITED right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $6.05M, a 60.07% decline from fiscal 2024.
- ZAI LAB LIMITED right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $15.15M, a 313.03% increase from fiscal 2023.
- ZAI LAB LIMITED right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $3.67M, a 75.22% decline from fiscal 2022.
- ZAI LAB LIMITED right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $14.80M, a 578.01% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $6.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.05M derived: sum of 2 quarters · filed 2026-02-26 | $6.05M derived: sum of 3 quarters · filed 2026-02-26 | $6.05M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $11.21M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $11.21M derived: sum of 3 quarters · filed 2026-02-26 | $12.76M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $11.21M derived: sum of 2 quarters · filed 2026-02-26 | $12.76M derived: sum of 3 quarters · filed 2026-02-26 | $12.76M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-12-31 | $11.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $12.76M derived: sum of 2 quarters · filed 2026-02-26 | $12.76M derived: sum of 3 quarters · filed 2026-02-26 | $15.15M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.55M derived: sum of 2 quarters · filed 2025-11-06 | $3.94M 10-Q · filed 2025-11-06 | $4.32M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.39M 10-Q · filed 2025-08-07 | $2.76M derived: sum of 3 quarters · filed 2026-02-26 | $2.74M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $2.40M 10-Q · filed 2025-05-08 | $2.77M derived: sum of 2 quarters · filed 2026-02-26 | $2.75M derived: sum of 3 quarters · filed 2026-02-26 | $3.40M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $372.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $355.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.01M derived: sum of 3 quarters · filed 2026-02-26 | $3.67M 10-K · filed 2026-02-26 | |
| 2023-09-30 | -$17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $634.00K derived: sum of 2 quarters · filed 2024-11-12 | $3.30M 10-Q · filed 2024-11-12 | $5.24M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $651.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $3.31M 10-Q · filed 2024-08-06 | $5.25M derived: sum of 3 quarters · filed 2025-02-27 | $9.66M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $2.66M 10-Q · filed 2024-05-08 | $4.60M derived: sum of 2 quarters · filed 2025-02-27 | $9.01M derived: sum of 3 quarters · filed 2025-02-27 | $12.87M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $6.35M derived: sum of 2 quarters · filed 2025-02-27 | $10.21M derived: sum of 3 quarters · filed 2025-02-27 | $14.80M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $4.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $8.27M derived: sum of 2 quarters · filed 2023-11-07 | $12.86M 10-Q · filed 2023-11-07 | $15.04M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $3.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $8.45M 10-Q · filed 2023-08-07 | $10.63M derived: sum of 3 quarters · filed 2024-02-27 | $10.63M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $4.60M 10-Q · filed 2023-05-09 | $6.78M derived: sum of 2 quarters · filed 2024-02-27 | $6.78M derived: sum of 3 quarters · filed 2024-02-27 | ||
| 2021-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $2.18M derived: sum of 2 quarters · filed 2024-02-27 | $2.18M 10-K · filed 2024-02-27 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | ||||
| 2020-12-31 | $6.39M 10-K · filed 2023-03-01 | ||||
| 2020-06-30 | $1.04M 6-K · filed 2020-09-11 | ||||
| 2019-12-31 | $10.88M 10-K · filed 2022-03-01 | ||||
| 2019-06-30 | $1.67M 6-K · filed 2020-09-11 | ||||
| 2019-01-01 | $100.00K 6-K · filed 2020-01-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |